Poseida Therapeutics, Inc. (PSTX) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Collaboration Revenue
011M22M34M45M56M68M79M90MQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
038M75M112M150M188M225M262M300MQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Operating Expenses

Research And Development ExpensesGeneral And Administrative ExpensesOther Expenses
09M18M26M35M44M52M61M70MQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024

EBITDA

EBITDA
-40M-31M-22M-14M-5M4M12M21M30MQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024

EPS

EPSEPS Diluted
000001111Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Revenue Variation (%)

Revenue Variation
-70-242269115161208254300Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
03875112150188225262300Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Revenue YoY Variation (%)

Revenue YoY Variation
-200-7550175300425550675800Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
01252503755006257508751KQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Price-to-Earning Ratio

P/E Ratio
-4-3-2-101234Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Income Breakdown

Operating IncomeTotal Other Income Expenses NetNet Income
06M12M19M25M31M38M44M50MQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000111222Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
012234456Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024
💰 Cash Flow Statement

Operating Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
011M22M34M45M56M68M79M90MQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Free Cash Flow

Cash At End Of Period
09M18M26M35M44M52M61M70MQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
025M50M75M100M125M150M175M200MQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024
🏦 Balance Sheet
📈 Key Metrics